Haemonetics licenses reagents for blood typing platform

Haemonetics has agreed a deal to license a number of blood typing reagents for use in a future laser-based system.

The medical device company has entered into a reagent development and supply agreement with Quotient Biodiagnostics subsidiary Alba Bioscience with the development of its Arryx blood typing platform in mind.

This deal will see Alba receive a number of milestone payments based on the future progress of Arryx, with Haemonetics due to deliver an update in May.

Brian Concannon, Haemonetics’ president and chief executive officer, expressed confidence that the Arryx system represents a market opportunity worth $1 billion (660 million pounds).

He said: “I am pleased to report this important milestone in our innovative nanotechnology development programme targeted at the blood diagnostics market.”

Last month, the company received approval from the Food and Drug Administration for its automated blood collection device Cymbal to be used among a wider range of female donors.